Figure 4.

Improved immunogenicity of neoantigen-peptide pulsed DC vaccine in the LP format. Nineteen LPs (21-mer), incorporating corresponding immunogenic 25 short mutated peptide sequences, were synthesized (Table S2). Three or four different LP-pulsed DCs were put together to produce five mixtures of DC vaccines: group A consists of L3, L12, L14, and L19 LPs; group B consists of L35, L43, L47, and L52 LPs; group C consists of L57, L58, L62, and L82 LPs; group D consists of L23, L39, L45, and L50 LPs; and group E consists of L51, L61, and L101 LPs. Mice were immunized twice at a 2-week interval. Two weeks after the last immunization, spleen cells were harvested and examined for the reactivity to the immunized LP by ex vivo ICS. IFN-γ production by CD8⁺ T cells (A) and CD4⁺ T cells (B) were evaluated by ICS. (C) Two weeks after the last immunization, LLC1 cells (1 × 10⁶) were subcutaneously inoculated (5 or 6 mice per group). Tumor growth was measured twice a week. * p < 0.05.